CD209 and myeloid sarcoma: MS-derived mo-DC show lower expression levels of DC-SIGN following 1,25(OH)2D3 treatment, despite the fact that both conventional and 1,25(OH)2D3-treated mo-DC from MS patients display significantly higher expression levels of DC-SIGN as compared to those of healthy controls (Supplementary Figure  1, in Supplementary Material available online at http://dx.doi.org/10.1155/2016/5392623).